SG Americas Securities LLC Acquires 3,374 Shares of Replimune Group, Inc. (NASDAQ:REPL)

SG Americas Securities LLC raised its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 14.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,291 shares of the company’s stock after purchasing an additional 3,374 shares during the quarter. SG Americas Securities LLC’s holdings in Replimune Group were worth $318,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Creative Planning lifted its holdings in shares of Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock valued at $231,000 after acquiring an additional 4,699 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after purchasing an additional 5,926 shares during the period. MetLife Investment Management LLC increased its position in shares of Replimune Group by 21.5% during the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company’s stock valued at $385,000 after purchasing an additional 6,216 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Replimune Group by 81.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after buying an additional 6,748 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Replimune Group by 3.3% during the third quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock worth $2,733,000 after buying an additional 8,074 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Trading Up 2.2 %

Shares of NASDAQ REPL opened at $14.01 on Wednesday. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The business has a fifty day simple moving average of $12.49 and a two-hundred day simple moving average of $11.54. The firm has a market cap of $958.56 million, a PE ratio of -4.59 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Analysts expect that Replimune Group, Inc. will post -2.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

REPL has been the topic of several recent analyst reports. BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright boosted their price objective on Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Finally, Jefferies Financial Group increased their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $19.14.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by corporate insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.